DEA Events Policy Safety 
Veriheal
JUNE 30, 2023
A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. To start, participants reported that psilocybin had helped them process emotions tied to painful events in their past.
Cannabis Law Report
JANUARY 22, 2020
It also directs the Commission to research “important current issues facing law enforcement and the criminal justice system,” and recommends a variety of subjects for study, such as, but not limited to” There is no direct mention of cannabis but a senior DEA appointment we would suggest is a message in itself. DEA Chief of Operations D.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veriheal
DECEMBER 1, 2022
This bill also directs the DEA to register manufacturers and distributors of CBD or marijuana for commercial production of an approved drug that contains marijuana or its derivative. This also would ensure that federal regulation protects public health and safety and prioritize restorative and economic justice.
Canna Law Blog
JULY 14, 2023
But, there’s a huge controversy about whether it can be controlled, with agencies like the DEA saying it is. FTC Policy Statement on Deception, 103 F.T.C. For now, stay tuned to the Canna Law Blog for more updates on FDA and FTC cannabinoid policies and delta-8 products. You can read more about that issue here or here.
Cannabis Law Report
SEPTEMBER 29, 2021
The membership subsequently met with the USDA’s new Hemp Work Group, and White House officials that serve the President on agriculture and drug control policy. Senators) who joined the group in a spirited, interactive discussion on hemp public policy. Check out some excerpts from press coverage of the event —.
Cannabis Law Report
APRIL 8, 2022
Later that year, Doblin sued the DEA for the first time. The FDA formally decided to open the door to psychedelic research in human participants, and later accepted MAPS’ Phase 1 MDMA safety and tolerance study protocol. submitted his first DEA application to manufacture marijuana for use in medical research.
FloridaMarijuana.net
JULY 8, 2018
The National Academies of Sciences reports that PTSD is a stressor-related disorder which develops as a result of a patient’s exposure to a traumatic event. MAPS worked for over 22 years to obtain marijuana for medical marijuana drug development research, and the approval is a historic shift in federal policy.
Expert insights. Personalized for you.
98 
Let's personalize your content